Hennigsdorf/Berlin (Germany), September 14, 2020 – Adrenomed AG, the vascular integrity company, announced today that data from the AdrenOSS-2 Phase II clinical trial with Adrecizumab in septic shock (NCT03085758[i]) will be presented during the International
Adrecizumab (HAM8101) showed a favourable outcome in a case series of eight COVID‐19 patients with life-threatening organ failure in ICU At publication, this represented the first data evaluating an experimental therapy in such late-stage COVID-19
The meeting “Global Burden, Diagnosis, and Adjunctive Therapies of Sepsis and COVID-19” will be available via livestream today, March 16, at 5:00 pm CET Adrenomed recently announced positive topline data from its AdrenOSS-2 Phase II
Adrecizumab, given on top of standard of care, was well tolerated and showed a favorable safety profile Adrecizumab demonstrates a positive trend on survival AdrenOSS-2 is a biomarker-guided (sphingotest bio-ADM®[1]) trial in sepsis Mode of
Proof-of-concept Phase II trial AdrenOSS-2 is assessing first-in-class antibody Adrecizumab, designed to restore and maintain vascular integrity AdrenOSS-2 trial design and Adrecizumab mode of action will be presented at the European Society of Intensive Care
Hennigsdorf/Berlin (Germany), August 29, 2019 – Adrenomed AG, the vascular integrity company, announced today that its Supervisory Board has appointed two new members of the Executive Board. Dr. Jens Schneider-Mergener is Chief Executive Officer (CEO)
Hennigsdorf (Germany), August 13, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation at four upcoming conferences in Europe. Adrenomed representatives will be available for networking and one-to-one meetings at the
Hennigsdorf (Germany), May 6, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation at three upcoming conferences in Europe and the USA. Adrenomed representatives will be available for one-on-one meetings at
AdrenOSS-II trial continues as planned after positive interim efficacy analysis triggered by the treatment of 50% of randomized patients Proof-of-concept trial design testing Adrecizumab in early septic shock presented at International Symposium on Intensive Care
Hennigsdorf (Germany), March 12, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation in three upcoming conferences in Europe. Adrenomed representatives will be available for one-on-one meetings at these events. 12th